Biocon Biologics Ltd (“BBL”) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) had issued positive ...

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment.

The once-daily, non-systemic ileal bile acid transport (IBAT) inhibitor was recommended for approval by the EMA's human medicines committee, the CHMP, in July 2023 for this indication under the ...

If the EMA follows the CHMP’s advice, Zynquista will become the second SGLT-acting drug to be approved for use alongside insulin in type 1 diabetes after AstraZeneca’s SGLT2 inhibitor Forxiga ...

SpringWorks Therapeutics, Inc. announced that it expects the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to issue an opinion on its marketing ...

LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

Alnylam Pharmaceuticals’ RNAi therapeutic vutrisiran has been recommended by the European Medicines Agency’s human medicines ...

“This positive CHMP opinion marks another important milestone in our efforts to bring vutrisiran to people around the world living with ATTR amyloidosis with cardiomyopathy,” said Pushkal ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the CD30-directed antibody-drug conjugate (ADC ...

"This positive CHMP opinion is a welcome step for physicians and patients in Europe who face a critical unmet need in HER2-positive biliary tract cancers, a rare and aggressive group of cancers ...

Alnylam Pharmaceuticals said its RNAi therapeutic vutrisiran received a positive opinion recommending approval from the Committee for Medicinal Products for Human Use of the European Medicines ...